avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2012-0-6-32-39avk-155Research ArticleБОЛЕЗНИ СЕРДЦА И СОСУДОВМЕТАБОЛИЧЕСКИЕ ЭФФЕКТЫ ОМЕГА–3 ЭФИРОВ ФИТОСТЕРОЛОВ У ПАЦИЕНТОВ С ГИПЕРЛИПИДЕМИЕЙ СМЕШАННОГО ТИПАМЕТАБОЛИЧЕСКИЕ ЭФФЕКТЫ ОМЕГА–3 ЭФИРОВ ФИТОСТЕРОЛОВ У ПАЦИЕНТОВ С ГИПЕРЛИПИДЕМИЕЙ СМЕШАННОГО ТИПАБитцурР.БитцурР.

г. Тель Ха–Шомер, Израиль

г. Тель Ха–Шомер, Израиль

Rafael.Bitzur@sheba.health.gov.ilКоенХ.КоенХ.

г. Тель Ха–Шомер, Израиль

г. Тель Ха–Шомер, Израиль

Rafael.Bitzur@sheba.health.gov.ilКоенЦ.КоенЦ.

г. Мигдаль а–Эмег, Израиль

г. Мигдаль а–Эмег, Израиль

ДрорТ.ДрорТ.

г. Мигдаль а–Эмег, Израиль

г. Мигдаль а–Эмег, Израиль

ХерцогЯ.ХерцогЯ.

г. Мигдаль а–Эмег, Израиль

г. Мигдаль а–Эмег, Израиль

ЛифшицЯ.ЛифшицЯ.

г. Мигдаль а–Эмег, Израиль

г. Мигдаль а–Эмег, Израиль

ЛюбишТ.ЛюбишТ.

г. Тель Ха–Шомер, Израиль

г. Тель Ха–Шомер, Израиль

Rafael.Bitzur@sheba.health.gov.ilХартсД.ХартсД.

г. Тель Ха–Шомер, Израиль

г. Тель Ха–Шомер, Израиль

Rafael.Bitzur@sheba.health.gov.ilРубинштейнА.РубинштейнА.

г. Тель–Авив, Израиль

г. Тель–Авив, Израиль

Липидный центр Берта В. Страссбургера Медицинского центра им. Хаиля ШибаИзраильЛипидный центр Берта В. Страссбургера Медицинского центра им. Хаиля ШибаIsraelR&D департамент компании Enzymotec LtdИзраильR&D департамент компании Enzymotec LtdIsraelR&D департамент компании Enzymotec LtdИзраильг. Мигдаль а–Эмег, ИзраильIsraelИнститут обмена веществ Медицинского центра «Сураски»ИзраильИнститут обмена веществ Медицинского центра «Сураски»Israel201228122012063239Copyright © Битцур Р., Коен Х., Коен Ц., Дрор Т., Херцог Я., Лифшиц Я., Любиш Т., Хартс Д., Рубинштейн А., 20122012Битцур Р., Коен Х., Коен Ц., Дрор Т., Херцог Я., Лифшиц Я., Любиш Т., Хартс Д., Рубинштейн А.Битцур Р., Коен Х., Коен Ц., Дрор Т., Херцог Я., Лифшиц Я., Любиш Т., Хартс Д., Рубинштейн А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/155

Целью данного исследования была оценка терапевтических эффектов омега–3 эфиров фитостеролов (n–3–PSE) на липидную составляющую и другие факторы риска у пациентов с гиперлипидемией смешанного типа. Было выяснено, что прием n–3–PSE не приводит к существенному изменению уровня липопротеинов. При этом наблюдалось существенное снижение уровня триглицеридов в группе, принимавшей n–3–PSE по сравнению с группой плацебо (р = 0,025). Отмечено снижение диастолического артериального давления (АД) и уровня С–реактивного белка (СРБ). Таким образом, прием n–3–PSE пациентами с гиперлипидемией смешанного типа может являться безопасной и эффективной терапией, направленной на снижение уровня триглицеридов (ТГ), одновременно исключающей типичное повышение уровня липопротеинов, связанного с приемом омега–3 жирных кислот (ЖК). Положительный эффект сохранился и после окончания исследования.

The aim of the current study was to evaluate the therapeutic effects of omega–3 plant sterol esters (n–3–PSE) on lipid profile and other coronary heart disease risk factors in subjects with mixed hyperlipidemia. N–3–PSE treatment did not result in a significant change in LDL–C levels. Triglyceride levels were reduced significantly in the n–3–PSE group in comparison with the placebo group (p = 0.025). Diastolic blood pressure and level of high-sensitivity C–reactive protein (hsCRP) were reduced significantly, too. So, in patients with mixed hyperlipidemia, n–3–PSE treatment may offer a safe and effective therapy for triglyceride level reduction while avoiding the typical increase in LDL–C levels associated with n–3 fatty acid treatment. The observed reduction in blood pressure and inflammation markers warrants further evaluation. The positive effect of n–3–PSE treatment was preserved at the end of the follow up phase.

гипертриглицеридемиядислипидемиярастительные стерольные эфирыомега–3 жирные кислотывысоко чувствительный С–реактивный белок (вчСРБ)hypertriglyceridemiadyslipidemiaplant sterol estersn–3 fatty acidshigh–sensitivity C–reactive protein (hsCRP)ReferencesAppel L.J., Miller 3rd E.R., Seidler A.J., Whelton P.K. Does supplementation of diet with ‘fish oil’ reduce blood pressure? A meta–analysis of controlled clinical trials. Arch Intern Med. 1993; 153(12):1429–38.Appel L.J., Miller 3rd E.R., Seidler A.J., Whelton P.K. Does supplementation of diet with ‘fish oil’ reduce blood pressure? A meta–analysis of controlled clinical trials. Arch Intern Med. 1993; 153(12):1429–38.Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C. et al. Efficacy and safety of cholesterol–lowering treatment: prospective meta–analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005; 366 (9493):1267–78.Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C. et al. Efficacy and safety of cholesterol–lowering treatment: prospective meta–analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005; 366 (9493):1267–78.Bays H. Clinical overview of Omacor: a concentrated formulation of omega–3 polyunsaturated fatty acids. Am J Cardiol. 2006; 98 (4A):71i–6.Bays H. Clinical overview of Omacor: a concentrated formulation of omega–3 polyunsaturated fatty acids. Am J Cardiol. 2006; 98 (4A):71i–6.Chiuve S.E., McCullough M.L., Sacks F.M., Rimm E.B. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipidlowering and antihypertensive medications. Circulation. 2006; 114 (2):160–7.Chiuve S.E., McCullough M.L., Sacks F.M., Rimm E.B. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipidlowering and antihypertensive medications. Circulation. 2006; 114 (2):160–7.Clifton P.M., Mano M., Duchateau G.S., van der Knaap H.C., Trautwein E.A. Dose–response effects of different plant sterol sources in fat spreads on serum lipids and C–reactive protein and on the kinetic behavior of serum plant sterols. Eur J Clin Nutr. 2008; 62(8):968–77.Clifton P.M., Mano M., Duchateau G.S., van der Knaap H.C., Trautwein E.A. Dose–response effects of different plant sterol sources in fat spreads on serum lipids and C–reactive protein and on the kinetic behavior of serum plant sterols. Eur J Clin Nutr. 2008; 62(8):968–77.Davidson M.H., Maki K.C., Kalkowski J., Schaefer E.J., Torri S.A., Drennan K.B. Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double–blind, placebo–controlled trial. J Am Coll Nutr. 1997; 16(3):236–43.Davidson M.H., Maki K.C., Kalkowski J., Schaefer E.J., Torri S.A., Drennan K.B. Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double–blind, placebo–controlled trial. J Am Coll Nutr. 1997; 16(3):236–43.De Jong A., Plat J., Bast A., Godschalk R.W., Basu S., Mensink R.P. Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low–grade inflammation in patients on current statin treatment. Eur J Clin Nutr. 2008; 62(2): 263–73.De Jong A., Plat J., Bast A., Godschalk R.W., Basu S., Mensink R.P. Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low–grade inflammation in patients on current statin treatment. Eur J Clin Nutr. 2008; 62(2): 263–73.Demonty I., Chan Y.M., Pelled D., Jones P.J. Fish–oil esters of plant sterols improve the lipid profile of dyslipidemic subjects more than do fish–oil or sunflower oil esters of plant sterols. Am J Clin Nutr. 2006; 84(6):1534–42.Demonty I., Chan Y.M., Pelled D., Jones P.J. Fish–oil esters of plant sterols improve the lipid profile of dyslipidemic subjects more than do fish–oil or sunflower oil esters of plant sterols. Am J Clin Nutr. 2006; 84(6):1534–42.Devaraj S., Autret B.C., Jialal I. Reduced–calorie orange juice beverage with plant sterols lowers C–reactive protein concentrations and improves the lipid profile in human volunteers. Am J Clin Nutr. 2006; 84(4):756–61.Devaraj S., Autret B.C., Jialal I. Reduced–calorie orange juice beverage with plant sterols lowers C–reactive protein concentrations and improves the lipid profile in human volunteers. Am J Clin Nutr. 2006; 84(4):756–61.Dietary supplementation with n–3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999; 354(9177):447–55.Dietary supplementation with n–3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999; 354(9177):447–55.Din J.N., Newby D.E., Flapan A.D. Omega 3 fatty acids and cardiovascular disease—fishing for a natural treatment. Bmj. 2004; 328(7430):30–5.Din J.N., Newby D.E., Flapan A.D. Omega 3 fatty acids and cardiovascular disease—fishing for a natural treatment. Bmj. 2004; 328(7430):30–5.Ewart H.S., Cole L.K., Kralovec J., Layton H., Curtis J.M., Wright J.L. et al. Fish oil containing phytosterol esters alters blood lipid profiles and left ventricle generation of thromboxane a(2) in adult guinea pigs. J Nutr. 2002; 132(6):1149–52.Ewart H.S., Cole L.K., Kralovec J., Layton H., Curtis J.M., Wright J.L. et al. Fish oil containing phytosterol esters alters blood lipid profiles and left ventricle generation of thromboxane a(2) in adult guinea pigs. J Nutr. 2002; 132(6):1149–52.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19):2486–97.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19):2486–97.Gaede P., Lund–Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358(6):580–91.Gaede P., Lund–Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358(6):580–91.Gaw A. HDL–C and triglyceride levels: relationship to coronary heart disease and treatment with statins. Cardiovasc Drugs Ther. 2003; 17(1):53–62.Gaw A. HDL–C and triglyceride levels: relationship to coronary heart disease and treatment with statins. Cardiovasc Drugs Ther. 2003; 17(1):53–62.Grundy S.M. Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am J Cardiol. 2005; 96(1A):47D–50.Grundy S.M. Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am J Cardiol. 2005; 96(1A):47D–50.Harris W.S. n–3 fatty acids and serum lipoproteins: animal studies. Am J Clin Nutr. 1997; 65(5 Suppl):1611S–6.Harris W.S. n–3 fatty acids and serum lipoproteins: animal studies. Am J Clin Nutr. 1997; 65(5 Suppl):1611S–6.Harris W.S., Bulchandani D. Why do omega–3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006; 17(4):387–93.Harris W.S., Bulchandani D. Why do omega–3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006; 17(4):387–93.Harris W.S., Ginsberg H.N., Arunakul N., Shachter N.S., Windsor S.L., Adams M. et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997; 4(5–6):385–91.Harris W.S., Ginsberg H.N., Arunakul N., Shachter N.S., Windsor S.L., Adams M. et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997; 4(5–6):385–91.Jacobson T.A. Myopathy with statin–fibrate combination therapy: clinical considerations. Nat Rev Endocrinol. 2009; 5(9):507–18.Jacobson T.A. Myopathy with statin–fibrate combination therapy: clinical considerations. Nat Rev Endocrinol. 2009; 5(9):507–18.Jacobson T.A. Role of n–3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr. 2008; 87(6):1981S–90.Jacobson T.A. Role of n–3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr. 2008; 87(6):1981S–90.Jemal A., Ward E., Hao Y., Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005; 294(10): 1255–9.Jemal A., Ward E., Hao Y., Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005; 294(10): 1255–9.Jones P.J., Demonty I., Chan Y.M., Herzog Y., Pelled D. Fish–oil esters of plant sterols differ from vegetable–oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor–1 (PAI–1) concentrations in hypercholesterolemic subjects. Lipids Health Dis. 2007;6:28.Jones P.J., Demonty I., Chan Y.M., Herzog Y., Pelled D. Fish–oil esters of plant sterols differ from vegetable–oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor–1 (PAI–1) concentrations in hypercholesterolemic subjects. Lipids Health Dis. 2007;6:28.Kelley D.S., Siegel D., Fedor D.M., Adkins Y., Mackey B.E. DHA supplementation decreases serum C–reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr. 2009; 139(3):Kelley D.S., Siegel D., Fedor D.M., Adkins Y., Mackey B.E. DHA supplementation decreases serum C–reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr. 2009; 139(3):–501.–501.Kris–Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega–3 fatty acids, and cardiovascular disease. Circulation. 2002; 106(21):2747–57.Kris–Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega–3 fatty acids, and cardiovascular disease. Circulation. 2002; 106(21):2747–57.Lee J.H., O’Keefe J.H., Lavie C.J., Marchioli R., Harris W.S. Omega–3 fatty acids for cardioprotection. Mayo Clin Proc. 2008; 83(3): 324–32.Lee J.H., O’Keefe J.H., Lavie C.J., Marchioli R., Harris W.S. Omega–3 fatty acids for cardioprotection. Mayo Clin Proc. 2008; 83(3): 324–32.Madsen T., Christensen J.H., Schmidt E.B. C–reactive protein and n–3 fatty acids in patients with a previous myocardial infarction: a placebo–controlled randomized study. Eur J Nutr. 2007; 46(7): 428–30.Madsen T., Christensen J.H., Schmidt E.B. C–reactive protein and n–3 fatty acids in patients with a previous myocardial infarction: a placebo–controlled randomized study. Eur J Nutr. 2007; 46(7): 428–30.McTaggart F., Jones P. Effects of statins on high–density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther. 2008; 22(4):321–38.McTaggart F., Jones P. Effects of statins on high–density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther. 2008; 22(4):321–38.Meyer B.J., Hammervold T., Rustan A.C., Howe P.R. Dosedependent effects of docosahexaenoic acid supplementation on blood lipids in statin–treated hyperlipidaemic subjects. Lipids. 2007; 42(2):109–15.Meyer B.J., Hammervold T., Rustan A.C., Howe P.R. Dosedependent effects of docosahexaenoic acid supplementation on blood lipids in statin–treated hyperlipidaemic subjects. Lipids. 2007; 42(2):109–15.Moreau R.A., Whitaker B.D., Hicks K.B. Phytosterols, phytostanols, and their conjugates in foods: structural diversity, quantitative analysis, and health–promoting uses. Prog Lipid Res. 2002; 41 (6):457–500.Moreau R.A., Whitaker B.D., Hicks K.B. Phytosterols, phytostanols, and their conjugates in foods: structural diversity, quantitative analysis, and health–promoting uses. Prog Lipid Res. 2002; 41 (6):457–500.Morris M.C., Sacks F., Rosner B. Does fish oil lower blood pressure? A meta–analysis of controlled trials. Circulation. 1993; 88(2): 523–33.Morris M.C., Sacks F., Rosner B. Does fish oil lower blood pressure? A meta–analysis of controlled trials. Circulation. 1993; 88(2): 523–33.Ninomiya J.K., L’Italien G., Criqui M.H., Whyte J.L., Gamst A., Chen R.S. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004; 109(1):42–6.Ninomiya J.K., L’Italien G., Criqui M.H., Whyte J.L., Gamst A., Chen R.S. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004; 109(1):42–6.Normen L., Shaw C.A., Fink C.S., Awad A.B. Combination of phytosterols and omega–3 fatty acids: a potential strategy to promote cardiovascular health. Curr Med Chem Cardiovasc Hematol Agents. 2004; 2(1):1–12.Normen L., Shaw C.A., Fink C.S., Awad A.B. Combination of phytosterols and omega–3 fatty acids: a potential strategy to promote cardiovascular health. Curr Med Chem Cardiovasc Hematol Agents. 2004; 2(1):1–12.Ostlund Jr R.E. Phytosterols in human nutrition. Annu Rev Nutr. 2002; 22:533–49.Ostlund Jr R.E. Phytosterols in human nutrition. Annu Rev Nutr. 2002; 22:533–49.Polanco N., Hernandez E., Gonzalez E., Gutierrez Martinez E., Bello I., Gutierrez–Millet V. et al. Fibrate–induced deterioration of renal function. Nefrologia. 2009;29(3):208–13.Polanco N., Hernandez E., Gonzalez E., Gutierrez Martinez E., Bello I., Gutierrez–Millet V. et al. Fibrate–induced deterioration of renal function. Nefrologia. 2009;29(3):208–13.Pollak O.J., Kritchevsky D. Sitosterol. Monogr Atheroscler. 1981; 10:1–219.Pollak O.J., Kritchevsky D. Sitosterol. Monogr Atheroscler. 1981; 10:1–219.Pownall H.J., Brauchi D., Kilinc C., Osmundsen K., Pao Q., Payton–Ross C. et al. Correlation of serum triglyceride and its reduction by omega–3 fatty acids with lipid transfer activity and the neutral lipid compositions of high–density and low–density lipoproteins. Atherosclerosis. 1999; 143(2):285–97.Pownall H.J., Brauchi D., Kilinc C., Osmundsen K., Pao Q., Payton–Ross C. et al. Correlation of serum triglyceride and its reduction by omega–3 fatty acids with lipid transfer activity and the neutral lipid compositions of high–density and low–density lipoproteins. Atherosclerosis. 1999; 143(2):285–97.Radack K.L., Deck C.C., Huster G.A. n–3 fatty acid effects on lipids, lipoproteins, and apolipoproteins at very low doses: results of a randomized controlled trial in hypertriglyceridemic subjects. Am J Clin Nutr. 1990; 51(4):599–605.Radack K.L., Deck C.C., Huster G.A. n–3 fatty acid effects on lipids, lipoproteins, and apolipoproteins at very low doses: results of a randomized controlled trial in hypertriglyceridemic subjects. Am J Clin Nutr. 1990; 51(4):599–605.Rader J.I., Calvert R.J., Hathcock J.N. Hepatic toxicity of unmodified and time–release preparations of niacin. Am J Med. 1992; 92 (1): 77–81.Rader J.I., Calvert R.J., Hathcock J.N. Hepatic toxicity of unmodified and time–release preparations of niacin. Am J Med. 1992; 92 (1): 77–81.Rauch B., Schiele R., Schneider S., Gohlke H., Diller F., Gottwik M. et al. Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarctionaims and methods of the OMEGA–study. Cardiovasc Drugs Ther. 2006;20(5):365–75. 436 Cardiovasc Drugs Ther (2010) 24:429–437.Rauch B., Schiele R., Schneider S., Gohlke H., Diller F., Gottwik M. et al. Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarctionaims and methods of the OMEGA–study. Cardiovasc Drugs Ther. 2006;20(5):365–75. 436 Cardiovasc Drugs Ther (2010) 24:429–437.Roche H.M., Gibney M.J. Effect of long–chain n–3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol metabolism. Am J Clin Nutr. 2000; 71(1 Suppl):232S–7.Roche H.M., Gibney M.J. Effect of long–chain n–3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol metabolism. Am J Clin Nutr. 2000; 71(1 Suppl):232S–7.Russell J.C., Ewart H.S., Kelly S.E., Kralovec J., Wright J.L., Dolphin P.J. Improvement of vascular dysfunction and blood lipids of insulinresistant rats by a marine oil–based phytosterol compound. Lipids. 2002; 37(2):147–52.Russell J.C., Ewart H.S., Kelly S.E., Kralovec J., Wright J.L., Dolphin P.J. Improvement of vascular dysfunction and blood lipids of insulinresistant rats by a marine oil–based phytosterol compound. Lipids. 2002; 37(2):147–52.Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S. et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation. 2007; 115(4):450–8.Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S. et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation. 2007; 115(4):450–8.Swahn E., von Schenck H., Olsson A.G. Omega-3 ethyl ester concentrate decreases total apolipoprotein CIII and increases antithrombin III in postmyocardial infarction patients. Clin Drug Investig. 1998; 15(6):473–82.Swahn E., von Schenck H., Olsson A.G. Omega-3 ethyl ester concentrate decreases total apolipoprotein CIII and increases antithrombin III in postmyocardial infarction patients. Clin Drug Investig. 1998; 15(6):473–82.Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25):3143–421.Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25):3143–421.Vissers M.N., Trip M.D., Pritchard P.H., Tam P., Lukic T., de Sain–van der Velden M.G. et al. Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia. Eur J Clin Pharmacol. 2008; 64(7):651–61.Vissers M.N., Trip M.D., Pritchard P.H., Tam P., Lukic T., de Sain–van der Velden M.G. et al. Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia. Eur J Clin Pharmacol. 2008; 64(7):651–61.Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y. et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open–label, blinded endpoint analysis. Lancet. 2007; 369(9567): 1090–8.Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y. et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open–label, blinded endpoint analysis. Lancet. 2007; 369(9567): 1090–8.

The authors declare that there are no conflicts of interest present.